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The US Food and Drug Administration (FDA) has four facilitated regulatory pathways
(FRPs): Fast Track (FT), Breakthrough Therapy (BTD), Priority Review (PR), and
Accelerated Approval (AA). Only PR specifies an expedited review timeline (6 months).
We sought to determine to what extent the combination of two or more FRPs influenced
development and approval times. We developed a “metro map” to illustrate FRP
elements and their influence on review times. We assessed 125 new active substances
(approved January 2013 to December 2015) 74 of which used one or more FRPs. For
these 74, development times ranged from 1,458 (BTD + PR + AA) to 3,515 days (PR).
PR alone had a median approval time of 242 days. The most common combination
was FT + PR (median approval 292 days, n = 21). The fastest approval times were
for PR + FT + BTD + AA (145 days) and PR + BTD + AA (166 days). Our findings
support the combination of FRPs for shortening development and review times beyond
that provided by PR alone.
Keywords: Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval, facilitated regulatory
pathway, FDA, review times
BACKGROUND
Patients have an expectation of rapid and efficient access to safe and effective, innovative new
medicines. This has raised expectations around the speed of the development and regulatory review
process. In the US, programs have sought to address these expectations, including the US Food and
Drug Administration’s (FDA) Critical Path Initiative which addresses the agency’s strategy to drive
innovation in the scientific processes through which medical products are developed, evaluated,
and manufactured. The FDA has taken a leadership role in implementing a variety of regulatory
pathways that provide sponsors with flexible options to facilitate development, and for the agency
to speed the regulatory review process without compromising standards for quality, safety, and
efficacy. Four expedited pathways for novel products for serious diseases or unmet medical need are
available: Fast Track designation (FT), Breakthrough Therapy designation (BTD), Priority Review
designation (PR), and Accelerated Approval pathway (AA). Their characteristics have been well
described elsewhere (FDA Guidance for Industry, 2014).
We previously termed these expedited pathways as facilitated regulatory pathways (FRPs):
regulatory pathways designed to speed the development, marketing authorization, and patient
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access to new drugs with a positive benefit–risk balance by
providing alternatives to standard product development and
regulatory review routes (Liberti et al., 2016). FRPs may increase
the level of communication and commitment between the
developer and the agency, can give a larger role to effects on
surrogate end points, and may move some of the burden of
evidence generation from the pre- to the post-authorization
phase. Since 2014, more than half of the new molecular entities
approved by the FDA used one or more FRPs (Bujar et al., 2015;
GAO Report, 2015). However, the extent to which the combined
use of these programs affects the time taken in the regulatory
review process remains unclear despite growing experience with
the programs.
One of the expedited pathways (PR) specifies a shortened
review timeline (6 months) and FT and BTD have been designed
to encourage interactions between the FDA and sponsors, thereby
seeking to shorten development times. Therefore, we sought to
determine to what extent these pathways influence development
times and whether the combination of two or more FRPs
influenced approval times compared to the use of PR alone. We
undertook an analysis of products recently approved by FDA
to assess the impact of the use of multiple combined FRPs on
drug development and approval time. We also developed a simple
methodology to illustrate the basic elements of these FRPS and
their influence on review times.
DISTINGUISHING ELEMENTS OF FDA
FRPS
The four FDA programs can be distinguished by several specific
characteristics (FDA Guidance for Industry, 2014), including
their temporal implementation sequence during development
and the nature of the minimally required supportive data: non-
clinical evidence of the potential to meet unmet medical need
(FT); preliminary human experience suggesting a substantial
improvement over available treatments based on a surrogate
or intermediate clinical end point (BTD); demonstration of a
meaningful therapeutic benefit over available therapies in clinical
studies using a surrogate or intermediate end point (AA); and
completed clinical trials that have demonstrated a significant
improvement in safety and/or efficacy (PR). None of these
programs are exclusive and any combination is permissible.
Three of these programs (FT, BTD, AA) have been designed
to encourage and expedite development. A product in early
development that is granted FT can be supported by early and
frequent interactions with reviewers. This support is extended
for products granted BTD through organizational commitment
from senior agency leadership and the opportunity to receive
additional intensive guidance beginning as early as Phase 1.
FT and BTD encourage an expedited review by permitting
the “rolling review” of sequentially submitted portions of
the submission. Products approved via AA are balanced by
rigorous post-authorization study commitments. Importantly,
PR decreases the statutory review time from 10 to 6 months.
Because outcomes of drug development are often difficult
to predict, designations may be rescinded if products do not
continue to meet defined criteria upon periodic reassessment.
The FT designation may be rescinded at any time if the
product no longer meets the qualifying criteria. Not all products
assigned BTD will be shown to have substantial improvement
over available therapies suggested by preliminary evidence;
if clinical benefit is not supported by subsequent data or
the non-completion of post-approval trials, the designation
may be rescinded. Products with a PR designation must
adhere to an integrated post-approval plan (the flexibility of
which is determined by the product characteristics, seriousness
of the condition and unmet medical need, manufacturing
processes, sponsor quality systems, strength of risk-based quality
assessment). Products approved via AA are subject to withdrawal
if the post-authorization confirmatory trials designed to verify
and describe the anticipated effect do not confirm the expected
outcomes.
Drug sponsors are required to submit formal requests to use
FT and BTD but not for PR (determined by FDA upon start of
the review) and AA (assigned by FDA at time of approval). From
2006 to 2014, the FDA Center for Drug Evaluation and Research
received about 1,000 requests for FT and BTD (GAO Report,
2015).
OBSERVATIONS
We analyzed new active substances (NAS) as previously defined
(Bujar et al., 2015) that received FDA approval between January
2013 and December 2015. Each was categorized as to the FRP(s)
used. Investigational new drug (IND) dates were obtained from
public domain data and from the Center for Research Innovation
in Biotechnology (CRIB) database 1. IND submission dates were
typically reported in these sources. Where a specific day was
not available, the 15th of the month was used. IND dates were
found for 68 products in this cohort. Times from IND date to
assignment of FT or BTD and to new drug application (NDA)
submission were calculated for each instance where dates were
available. Time from NDA submission to approval date was
calculated based on data obtained from the FDA website. This
time in calendar days includes both agency review time and
company response time.
We employed a “metro map” approach to illustrate the
relationship between the key aspects of each FRP, the touch points
and temporal relationship among them, and the length of the
regulatory review times when these programs were employed.
Figure 1 illustrates the key steps for each of the four programs,
from pre-IND through to post-authorization. The process begins
at the upper left region addressing factors related to acceptance
and the product’s characteristics. A product may then follow
one of several pre-designation routes to a point at which a
designation is assigned (a standard review is always an option and
therefore is not illustrated here). The combination of FRP routes
result in varying approval times, designated by the tracks in the
Review Period sector. The relative length of the review period
line corresponds to the median review time; the “node” size at
1http://db.crib.wustl.edu
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FIGURE 1 | “Metro Map” analysis of FDA FRPs and influence on median approval times.
the end of the line reflects the number of products that followed
that route.
Among the 125 NAS approved during this period, 74 (59%)
used one or more FRP. No products in this cohort used BTD
alone, FT+ BTD, BTD+ AA, or FT+ AA+ BTD.
Development times (time from IND to NDA submission) were
influenced by the FRP route (Figure 2). The median development
time for products using any FRP was 2,377 days and for products
not using an FRP (standard reviews) was 2,148 days. Products
that used BTD+ PR+AA had the shortest median development
time (1,458 days). By contrast, products that were approved by FT
or PR alone had the longest development time (2,620 and 3,515
days, respectively).
Poirier (Poirier and Murphy, 2016) observed that for non-
oncology products and vaccines BTD had little impact on
development timelines and that AA appeared to influence
timelines more than BTD. We observed that for this recent mixed
product cohort, the provisions offered by FT and BTD resulted
in shorter development times when used in combination with
other FRPs. The underlying factors that influence development
should be explored, as more products avail themselves of these
designations throughout their research phase. The characteristics
of the products, influence of unmet medical need, number and
outcomes of advice meeting with the agency, nature of the clinical
trials or other measures could provide insights into the influence
of these FRPs on development program efficiency. Similarly, an
analysis of whether products that use an FRP during development
stage are more likely to receive first cycle approval could point
to what extent FRP use can be a predictor of more efficient
regulatory processes.
In terms of regulatory review, the median approval time
for the 74 products that used an FRP was 243 days compared
to a median 365 days for the 51 products that did not use
any FRP (standard reviews). PR alone had a median review
time of 242 days. The most common FRP combination was
FT + PR; the median approval time for the 21 products in this
category was 292 days. The three fastest review times cohorts
were PR + FT + BTD + AA (145 days), PR + BTD + AA (166
days), and PR + FT + BTD (242 days). The median approval
times and 25th to 75th percentiles for FRPs used alone or in
combination during the analysis time period used by five or more
products are presented in Figure 3. The median approval times
for FRPs used by the remaining products were AA (n = 1; 1,034
days), FT + AA (n = 1; 304 days), PR + AA (n = 2; 328 days),
BTD + PR (n = 3, 193 days), and FT + AA + PR (n = 2; 543
days).
The median approval time for PR + FT + BTD was similar
to that of PR alone suggesting that PR is a driver of shortened
review time. The cohorts with the shortest review times also
received AA. This program gives the agency the flexibility to
approve products used for serious or unmet conditions (and
with a positive benefit–risk profile) more rapidly on the basis
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FIGURE 2 | Median development times (IND to NDA submission) for products that followed one or more FRPs.
FIGURE 3 | Median time for FDA approvals for products that followed one or more FRPs.
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of a surrogate or intermediate efficacy endpoint; expedited
access is balanced against post-authorization commitments of
continuous assessment of the product’s safety and efficacy linked
to disengagement and withdrawal processes if the expected
outcomes are not attained.
The use of all four FRPs together was associated with the
fastest median approval time (145 days), and this likely reflected
the critical importance of the products assessed. All five products
that qualified for use of all four FRPs (ibrutinib, idelalisib,
nivolumab, osimertinib mesylate, daratumumab) are indicated
for the treatment of serious oncologic conditions where there is a
high unmet medical need.
When the median development and approval times were taken
together, the time from IND to approval was 2,620 days for
products that used an FRP and 2,513 days for those that did
not use an FRP. Importantly, the shortest overall time from
IND to approval was for the cohort of BTD + PR + AA
(1,624 days). Combinations of FRPs contributed to faster overall
times from IND to approval: FT + BTD + PR (1,720 days);
FT + PR (2,308 days); FT + BTD + PR + AA (2,434 days).
The longest times were FT alone (2,981 days) and PR alone
(3,757 days).The FDA has worked closely with sponsors to
manage adherence to post-authorization commitments from
FRPs. Where these are not fulfilled, the products may be
withdrawn. In a recent example, the FDA approved lutropin
alpha for use in infertile hypogonadotropic hypogonadal women
under the AA pathway. Subsequently, the sponsor (EMD Serono)
requested that FDA withdraw approval of the drug noting that it
was not feasible to complete a trial that the company had agreed
to at the time of approval; the application was withdrawn in
2016.
BTD has recently been shown to contribute to review times
that were faster than target dates defined by Prescription
Drug User Fee Act (PDUFA) (Kalesnik-Orszulak et al., 2016).
Because BTD was recently instituted (2012) many of the
products in this cohort may not have been fully supported
by the designation throughout their development cycle; on-
going assessments of new approvals will help define the
contribution of BTD to the review timeline. Our findings support
the value of the combination of FRPs for shortening review
times beyond that provided by PR alone. These observations
raise questions about the perceived market value of “Priority
Review Vouchers (PRV)” wherein an eligible company can
use the voucher to have any one of their drugs reviewed
under PR.
APPLICATION TO OTHER FRPS
The nature of the data available during a product’s development
underpins the selection, sequence, and confluence of FRPs. For
example, not all products for serious or unmet medical need
qualify for, or may find use of all FDA FRPs. However, the
mapping approach presented herein can help illustrate how
these programs fit into the overall product development and
review process, the interconnections between the designations
and pathway, and the relationship of their use to development
strategies and approval times.
Similar research can be conducted to provide metrics around
the use of novel FRPs in other International Council for
Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH) countries [e.g., Conditional Marketing
Authorization, Accelerated Assessment, Priority Medicines in the
European Medicines Agency (EMA), Early Access to Medicines
Scheme in the UK, Sakigake at Pharmaceuticals and Medical
Devices Agency (PMDA)], and to assess the outcomes of activities
associated with novel adaptive pathways. The utilization of the
metro map visualization can serve as a platform to illustrate
the requirements, touch points and influence on development,
review and approvals times of these FRPs.
The metro map process can also assist in illustrating the routes
and timings of specific FRPs often relied upon by maturing
regulatory agencies [e.g., the World Health Organization (WHO)
prequalification routes, EMA Article 58]. Furthermore, this
approach can provide transparency around FRPs being developed
and implemented by maturing agencies and regional alignment
initiatives around the world (Liberti et al., 2016) and can
help identify the different procedures and routes available to
enable efficient outcomes through the appropriate application of
FRPs.
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